英夫利昔单抗治疗强直性脊柱炎临床观察  

Clinical Observation of Effect of Infliximab on Ankylosing Spondylitis

作　　者：吴斌[1,2] 朱宁[1,2] 毛静[1,2] 梁彩霞[1,2] 蔡烈凤[1,2] 张晓莲[1,2] 

机构地区：[1]长江大学附属第一医院 [2]荆州市第一人民医院血液风湿科,湖北荆州434000

出　　处：《长江大学学报（自然科学版）》2011年第4期141-142,134-135,共2页Journal of Yangtze University(Natural Science Edition)

摘　　要：目的：观察注射用英夫利西单抗（infliximab,商品名：类克Remicade）治疗强直性脊柱炎（AS）的临床疗效和安全性。方法：20例活动性AS患者分为治疗组10例和对照组10例。治疗组在每周口服甲氨蝶呤（MTX）10~15mg基础上联合应用英利昔单抗（类克）,在第0、2、6周接受3mg/kg的英利昔单抗静脉滴注;对照组口服相同剂量的MTX,联合应用其他改变病情药（DMARDs）,如柳氮磺胺吡啶、来氟米特,疗程均为12周。结果：治疗组和对照组治疗后AS活动指数（BASDAI）、脊柱痛、胸廓扩张度、Schober及CRP、ESR等指标较治疗前均明显改善,差异均有统计学意义（P〈0.05）。且治疗组各项观察指标改善程度明显优于对照组,差异有统计学意义（P〈0.05）。治疗组最常见的不良反应主要是上呼吸道感染及少见的皮肤损害。结论：类克是安全有效的治疗AS的药物,可以更早期的达到诱导缓解病情的目的。Objective:To observe the efficacy and safety of infliximab on ankylosing spondylitis(AS).Methods:20 patients with active AS were divided into treatment group and control group(10 cases,respectively).The treatment group was given weekly oral methotrexate(Methotrexate,MTX) along with 10～15mg infliximab,receiving 3mg/kg at 0,2,6 weeks of intravenous infliximab drip;the control group was given the same dose of MTX,with the disease-modifying anti-rheumatic drugs(DMARDs),such as salicylazosulfapyridine(SASP) and leflunomide.The course of treatment was 12 weeks.Results:The treatment group and the control group after treatment had an ankylosing spondylitis disease activity score(ASDAS).Their spine pain,thoracic distension,Schober and CRP,ESR and other indicators were significantly improved compared with before treatmen,the difference was statistically significant(P<0.05).All improved indexes of the treatment group were better than those of the control group,the difference was statistically significant(P<0.05).The most common adverse reactions in treatment group are mainly the upper respiratory tract infection and the rare skin damage.Conclusion:Infliximab proves to be a safe and effective drug for AS which may play a part in the remission.

关 键 词：强直性脊柱炎 英夫利西单抗 甲氨蝶呤 

分 类 号：R593.23[医药卫生—内科学]